Case report reveals severe vision loss in a man with bladder cancer undergoing pembrolizumab treatment, suggesting serious ocular risks.
This case report describes a 70-year-old man with bilateral vision loss due to cancer-associated retinopathy exacerbated by pembrolizumab.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: